Mitochondrial dysfunction and neurodegeneration in multiple sclerosis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) has traditionally been considered an autoimmune inflammatory disorder leading to demyelination and clinical debilitation as evidenced by our current standard anti-inflammatory and immunosuppressive treatment regimens. While these approaches do control the frequency of clinical relapses, they do not prevent the progressive functional decline that plagues many people with MS. Many avenues of research indicate that a neurodegenerative process may also play a significant role in MS from the early stages of disease, and one of the current hypotheses identifies mitochondrial dysfunction as a key contributing mechanism. We have hypothesized that pathological permeability transition pore (PTP) opening mediated by reactive oxygen species (ROS) and calcium dysregulation is central to mitochondrial dysfunction and neurodegeneration in MS. This focused review highlights recent evidence supporting this hypothesis, with particular emphasis on our in vitro and in vivo work with the mitochondria-targeted redox enzyme p66ShcA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial formation of reactive oxygen species
Turrens, J. F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.049478 · Cited by 5,084
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
The p66shc adaptor protein controls oxidative stress response and life span in mammals
Migliaccio, E., Giorgio, M., Mele, S., Pelicci, G., Reboldi, P., Pandolfi, P. P., Lanfrancone, L., & Pelicci, P. G. (1999) · Nature · doi:10.1038/46311 · Cited by 1,712
A Distinct Pathway Remodels Mitochondrial Cristae and Mobilizes Cytochrome c during Apoptosis
Scorrano, L., Ashiya, M., Buttle, K., Weiler, S., Oakes, S. A., Mannella, C. A., & Korsmeyer, S. J. (2002) · Developmental Cell · doi:10.1016/s1534-5807(01)00116-2 · Cited by 1,072
ROS, mitochondria and the regulation of autophagy
Scherz-Shouval, R., & Elazar, Z. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.009 · Cited by 954 · cited 1×
“Furthermore, increased intracellular production of oxidative agents, in particular, mitochondria-localized ROS, has been shown to exacerbate neuronal distress in multiple neurodegenerative disease models (Fiskum et al., 2003; Scherz-Shouval and Elazar, 2007).”
BackgroundSchinzel, A. C., Takeuchi, O., Huang, Z., Fisher, J. K., Zhou, Z., Rubens, J., Hetz, C., Danial, N. N., Moskowitz, M. A., & Korsmeyer, S. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505294102 · Cited by 820 · cited 1×
“Similarly, Schinzel et al. found that CyPD-KO mice were significantly protected from brain ischemia/reperfusion injury via middle cerebral artery occlusion, demonstrating a 62% reduction in brain infarct size (Schinzel et al., 2005).”
BackgroundProperties of the Permeability Transition Pore in Mitochondria Devoid of Cyclophilin D
Basso, E., Fante, L., Fowlkes, J., Petronilli, V., Forte, M. A., & Bernardi, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500089200 · Cited by 808 · cited 1×
“Consequently, the mitochondria in CyPD-KO mice are able to retain about double the amount of Ca2+ as mitochondria from wild-type (WT) animals before PTP activation, demonstrating that CyPD is a significant regulator of PTP opening (Baines et al., 2005; Basso et al., 2005).”
BackgroundSelf-citationA reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T., & Kerschensteiner, M. (2011) · Nature Medicine · doi:10.1038/nm.2324 · Cited by 713 · cited 3×
“…compelling evidence of mitochondrial dysfunction from in vivo imaging of double-transgenic mice with CFP-labeled mitochondria and YFPlabeled axoplasm (Thy1-MitoCFP × Thy1-YFP16) induced with experimental autoimmune encephalomyelitis (EAE), a commonly used animal model for MS (Nikic et al., 2011).”
BackgroundResult
Cited by
Diabetes, oxidative stress and therapeutic strategies
Rochette, L., Zeller, M., Cottin, Y., & Vergely, C. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.05.017 · Cited by 530
Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling
Wu, Y., Chen, M., & Jiang, J. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.07.003 · Cited by 385
Hu, C., Nydes, M., Shanley, K. L., Morales Pantoja, I. E., Howard, T. A., & Bizzozero, O. A. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14604 · Cited by 200
Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology
Bonora, M., Patergnani, S., Ramaccini, D., Morciano, G., Pedriali, G., Kahsay, A., Bouhamida, E., Giorgi, C., Wieckowski, M., & Pinton, P. (2020) · Biomolecules · doi:10.3390/biom10070998 · Cited by 135
“Additionally, impaired mitochondrial enzyme complex activity [133,134], increased oxidative stress [135], altered mitochondrial DNA [136], impaired quality control systems [137,138], and abnormal mitochondrial number and morphology have been described in MS patients [133] and in vivo MS mouse models [139,140].”
BackgroundWarne, J., Pryce, G., Hill, J. M., Shi, X., Lennerås, F., Puentes, F., Kip, M., Hilditch, L., Walker, P., Simone, M. I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.700385 · Cited by 99
“Whereas brain levels may be higher at Cmax, it is also probable that brain levels and importantly spinal cord levels may be significantly higher in animals with active and chronic EAE, which exhibit mainly spinal cord disease, due to alterations in metabolism and blood-brain barrier breakdown that occurs in EAE and MS…”
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression
Albanese, M., Zagaglia, S., Landi, D., Boffa, L., Nicoletti, C. G., Marciani, M. G., Mandolesi, G., Marfia, G. A., Buttari, F., Mori, F., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0502-1 · Cited by 88
Abbasi-Kangevari, M., Ghamari, S.-H., Safaeinejad, F., Bahrami, S., & Niknejad, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00238 · Cited by 79
“In addition, damage to mitochondrial DNA and mitochondrial enzyme complexes may lead to neurodegeneration (44).”
BackgroundIron chelation and multiple sclerosis
Weigel, K. J., Lynch, S. G., & LeVine, S. M. (2014) · ASN NEURO · doi:10.1042/an20130037 · Cited by 63
“Mitochondrial dysfunction may promote pathology during both acute inflammatory events as well as during the progression of neurodegeneration (Su et al., 2013).”
BackgroundMitochondrial Impairment in Oligodendroglial Cells Induces Cytokine Expression and Signaling
Scheld, M., Fragoulis, A., Nyamoya, S., Zendedel, A., Denecke, B., Krauspe, B., Teske, N., Kipp, M., Beyer, C., & Clarner, T. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1236-6 · Cited by 17
Metadata
- Authors
- Su, K., Bourdette, D., & Forte, M.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 169-169
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W2156127065
- Cited by
- 93
- References
- 18
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.